Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.66 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.66 |
| ▸ | PRKG1 | Q13976 | 3/20 | 0.66 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.66 |
| ▸ | CDK1 | P06493 | 2/20 | 0.66 |
| ▸ | PRKACA | P17612 | 2/20 | 0.66 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.66 |
| ▸ | CDK2 | P24941 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | GSK3A | P49840 | 2/20 | 0.66 |
| ▸ | GSK3B | P49841 | 2/20 | 0.66 |
| ▸ | PRKX | P51817 | 2/20 | 0.66 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.66 |
| ▸ | PRKG2 | Q13237 | 2/20 | 0.66 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.66 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.66 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.66 |
| ▸ | SGK2 | Q9HBY8 | 2/20 | 0.66 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.66 |
| ▸ | CSF1R | P07333 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21877013 | 1.00 | ROCK2 (0.66) | ROCK2ROCK1PRKG1RPS6KA5CDK1 | |
| SCHEMBL3829625 | 0.89 | KMT2A (0.58) | ROCK2ROCK1PRKG1RPS6KA5CDK1 | |
| SCHEMBL1697693 | 0.86 | ROCK2 (0.61) | ROCK2ROCK1PRKG1RPS6KA5CDK1 | |
| SCHEMBL9931517 | 0.86 | ROCK2 (0.61) | ROCK2ROCK1PRKG1RPS6KA5CDK1 | |
| SCHEMBL9931061 | 0.86 | ROCK2 (0.61) | ROCK2ROCK1PRKG1RPS6KA5CDK1 | |
| SCHEMBL17571990 | 0.84 | ALDH1A1 (0.61) | ROCK2ROCK1PRKG1RPS6KA5CDK1 | |
| SCHEMBL1697497 | 0.83 | ACACA (0.59) | ROCK2ROCK1PRKG1RPS6KA5CDK1 | |
| SCHEMBL1697500 | 0.83 | ACACA (0.59) | ROCK2ROCK1PRKG1RPS6KA5CDK1 | |
| SCHEMBL9931091 | 0.83 | ROCK1 (0.58) | ROCK2ROCK1PRKG1RPS6KA5CDK1 | |
| SCHEMBL9931090 | 0.83 | ROCK1 (0.58) | ROCK2ROCK1PRKG1RPS6KA5CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3846907-A1 | POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | Arvinas Operations, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | ROCK2 1208/4885ROCK1 2114/4885PRKG1 1464/4885 |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | CRBN, ARAF, VHL | ROCK2 1208/4885ROCK1 2114/4885PRKG1 1464/4885 |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | ROCK2 1208/4885ROCK1 2114/4885PRKG1 1464/4885 |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | ROCK2 1208/4885ROCK1 2114/4885PRKG1 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.